Cambridge, United States
MNM Bioscience, founded in 2018, is at the forefront of merging AI and biotechnology to revolutionize cancer therapy. Based in the United States, their slogan, "From tumor genomes to AI-driven drug discovery," encapsulates their innovative approach to oncology.
The company is committed to uncovering clinically valuable insights from tumor genomes. By integrating advanced genome analysis with cutting-edge AI, MNM Bioscience has developed tools that provide critical answers to patients and clinicians. Their proprietary CDK4/6i, HRD, and PD1i patient stratification algorithms set them apart in the life sciences and pharmaceutical industries.
The recent development of their drug, MNM177, signifies a new direction away from traditional drug target discovery, starting with real patient data to find relevant target candidates. Their last funding round was a Seed Round on 20 October 2020, raising $2.44M from investors Black Pearls VC and RTA.vc.
